<DOC>
	<DOCNO>NCT00425321</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability 100 , 200 , 300 mg/day dos RWJ-445380 12 week patient active Rheumatoid Arthritis despite methotrexate therapy .</brief_summary>
	<brief_title>Safety Effectiveness Study RWJ-445380 Cathepsin-S Inhibitor Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>Trials new , first -in-class drug do ascertain safety , tolerability , explore efficacy treatment rheumatoid arthritis , include effect biomarkers . Approximately 240 adult patient rheumatoid arthritis despite use methotrexate therapy recruit study . They randomly assign one 4 treatment arm ; patient equal chance receive placebo , 100 mg , 200 mg , 300 mg dose RWJ-445380 . Patients take medication daily 12 week . Patients receive study medication blind fashion , i.e . patient , doctor study sponsor know group patient patient complete study . The investigator sponsor monitor study occurrence possible side effect . In addition screen visit , patient visit every week first 2 week every 2 week 12 week treatment . After 12 week , followup visit 4 week last dose study drug take . Medical history , physical examination , blood pressure , heart rate , temperature , ECGs check periodically . Joints assess explore whether drug might affect tender swollen joint . Blood sample take standard safety laboratory test well special test drug blood level , biomarkers see whether drug might affect biological pathway antigen presentation , marker rheumatoid arthritis . Samples also take see whether certain type immune cell affect take drug . Immunization tetanus vaccine do see take drug might affect immune response agent Patients receive RWJ-445380 , 100 , 200 , 300 mg , placebo . Patients receive oral capsule daily 12 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients diagnose rheumatoid arthritis least 6 month least 8 tender 8 swollen joint methotrexate treatment 6 month least 10mg/wk stable dose least 8 week negative TB screening Use diseasemodifying antirheumatic drug ( DMARDs ) ( Methotrexate MTX ) previous use 1 antiTNF ( tumor necrosis factor ) agent previous use cytotoxics , p38 MAPkinase inhibitor , antiCD4 antibody receipt live vaccine within 1 month study drug serious infection previous 2 month history chronic recurrent infectious disease history opportunistic infection clinically significant disease organ system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Joints</keyword>
	<keyword>Auto immune</keyword>
</DOC>